There is going to be a vaccine against relapse

The smokers can soon get vaccines to help them break bad habits thanks to the cooperation between Glaxo Smith Kline (GSK) pharmaceutical companies and Nabi Pharmaceuticals.

Researchers from the two companies envisaged that the NicVac vaccine they created would prevent nicotine from reaching the brain, avoiding the sense of addiction. The test showed that the vaccine produced in the study room halved the risk of relapse among smokers.

In fact, the effectiveness of pharmaceuticals that have helped to permanently quit smoking has been underestimated. Data from the American Lung Association said that the rate of relapse within a year is very high, about 90%.

The injected vaccine will work by creating an antibiotic that binds nicotine molecules, preventing them from entering the bloodstream and going to the brain.

However, the idea of ​​injecting vaccines into the body creates resistance that binds nicotine molecules, preventing them from entering the bloodstream and going to the untested brain. If successful, the vaccine will open up prospects for preventing millions of tobacco-related deaths worldwide.

Under the cooperation agreement, GSK will prepay £ 24 million (UK) to Nabi to study vaccines. If Nabi succeeds, GSK will spend an extra amount of 296 million pounds to own the invention to help them become a key unit in the market for smoking cessation drugs.